Making Reflexive Testing the Standard of Care in Lung Cancer: Robert Kratzke, MD
There is a great need to streamline the process from the tissue sample to the diagnostic lab, whether it's genomic or immunohistochemistry, Robert Kratzke, MD, says.
Ensuring Coverage of Faster Biomarker Testing in Lung Cancer: Robert Kratzke, MD
Robert Kratzke, MD, urged insurance providers to prioritize fast biomarker testing in non–small cell lung cancer, saying it’s both cost-effective and life-saving.
